歐康維視生物(01477.HK)治療老視滴眼液獲批內地III期臨床
歐康維視生物-B(01477.HK)公布,針對老視適應症的自主研發產品OT802(鹽酸毛果芸香鹼滴眼液)III期臨床試驗授權近日獲得國家藥品監督管理局藥品審評中心批准,可開展一項隨機、雙盲、安慰劑對照、平行組、多中心臨床試驗。
該滴眼液用於治療老視。臨床前研究表明,OT-802具有起效快、安全性高的特點。集團就OT-802應用與OT-101相同的液液雙腔製劑技術,有效應對產品穩定性挑戰。集團指擁有該項專有技術的獨家專利權,並將盡快啟動OT-802 III期臨床試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.